Radafaxine is drug candidate designated GW-353162 by GlaxoSmithKline investigated for treatment of restless leg syndrome and as an NDRI antidepressant. GlaxoSmithKline was targeting Radafaxine for regulatory filing in 2007 but development was discontinued in 2006 due to poor test results.[citation needed]
This page contains content from the copyrighted Wikipedia article "Radafaxine"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
